🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

If you’re looking for a great review on approach to diagnosing and treating patients with Pheo and Para- look no further. Hussam Alkaissi Jaydira Del Rivero, MD #KarelPacak et al discuss the latest in the care of patients with Pheo/Para in this excellent review 🔥 Pheo Para Alliance Neuroendocrine Cancer Foundation

NEWS FROM INDUSTRY🚨 Source AstraZeneca DESTINY-Breast11 Update The DESTINY-Breast11 Phase III trial sees trastuzumab deruxtecan followed by paclitaxel, trastuzumab, and pertuzumab (THP) improved pathologic complete response rates compared to the standard neoadjuvant regimen of

🚨 DESTINY-Breast11: T-DXd followed by THP significantly 🔼pCR vs ddAC-THP in high-risk HER2+ EBC & better safety profile. Neoadjuvant landscape shifting? Excited to see full efficacy + safety data in the paper. Paolo Tarantino Ashish Singh OncoAlert OncoDaily Goutham Sunny #bcsm

🎉 Out work from Princess Margaret Cancer Centre is out now in the European Journal of Hematology! Outcomes of allogeneic transplantation for MDS/MPN overlap neoplasms in the contemporary era 🙌🏽 Hans Messner Allogeneic BMT Program Sergio Rodríguez-Rodriguez, MD, MHSc. 🇲🇽 onlinelibrary.wiley.com/doi/abs/10.111…

Lessons from Dr Emil Freireich False negative results are much more harmful than false positives. With false negatives, whole fields of inquiry may be shuttered. With false positives, others will try to replicate the data or build on it, and the false positive will be exposed.

1/n..Under the aegis of CRSF - Cancer Research and Statistic Foundation and guidance of Dr (Prof). Vijay Patil, Vanita Noronha, MBBS MD DM, Dr. Kumar sir, our long-awaited study on Triple Metronomic therapy was published in The Cancer Letter. Please read and comment. kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2…

Another DNB thesis lands in my inbox—joining its MD cousins. My task is to evaluate it. A formality, really. The postgraduate has written it, the professor has supervised it—or so the paperwork claims. I enter the username, type the password, and open the file—without hope. An

One of my favorite posters of #ESMOBreast25, addressing an important question: 👉What is the outcome of post-T-DXd treatments in HER2+ mBC? Does T-DXd-induced HER2 downregulation impair the activity of subsequent T-DM1? TKIs? Chemo? Answer below 1/4

This is so reassuring Kevin Kalinsky, MD, MS, FASCO #TNBC

Ph2 trial in🇨🇳 (n=100) in unresectable stage III NSCLC: anti–PD-1 induction therapy achieved 61.7% MPR. ⚠️BST1 (AUC 0.78) identified as a predictive biomarker in PD-L1–neg/unevaluable tumors, linked to CD8+/NK infiltration and better EFS/OS (p<0.05) rdcu.be/emeHn

Excellent response to tramatinib plus low-dose doxorubicin in RAF1-mutated sarcoma. ecancer.org/en/journal/art… 1. CD 34 and S 100 coexpression (just like NTRK and RET fusion sarcomas) 2. PZRN3-RAF1 misdiagnosed as DFSP

Does the dose of Dexamethasone matter in the management of MM? Tune into the IMAGe Journal club on 22 May at 1730h IST for a better understanding of the long-considered backbone of MM therapy. Also, hear about the MM care in Sri Lanka. Rahul Banerjee, MD, FACP Buddhika Somawardana

Proud to share our new publication in Nature Communications , led by Oscar Arrieta and an extraordinary team effort Instituto Nacional de Cancerología . Alectinib + bevacizumab as 1L therapy in metastatic ALK+ NSCLC 🫁: 🔹 ORR: 100% 🔹 12 & 36 month PFS: 97% & 64.2% 🔹 36-month intracranial PFS: 87.8% 👉While not

Second Primary malignancies (SPM) post transplant are rarely reported from India. It requires really long follow-up of big cohorts to show this data. Happy to share our recent publication on SPM post transplant in myeloma link.springer.com/article/10.100…

💰 The 2026 NCI budget drops from $7.22B to $4.10B—a 43% cut 📉. How will this impact the future of cancer research? 🧠 Has your research been impacted? ARTICLE: oncologytube.com/2026-cancer-re… YOUTUBE: youtu.be/DQrD_PpVMF4 OncoAlert ASCO Mark Lewis, MD, FASCO Stephen V Liu, MD Mike Thompson, MD, PhD, FASCO

🚨 Just published in JCO Global Oncology 📢 Our phase III METRO-CHASE trial shows triple oral metronomic chemotherapy significantly improves survival in platinum-refractory. #HeadAndNeckCancer. 🔗 doi.org/10.1200/GO-25-… #oncology #cancerresearch

🎖️Day 2 of #ASCO25 at ASCO TECAG lounge with a full agenda! ASCO ✨Come join us for excellent panels, networking opportunities, one-on-one mentorship and to relax, recharge and grab snacks & coffee! Agenda 👉cdn.bfldr.com/KOIHB2Q3/as/7c… #MedEd Rami Manochakian MD, FASCO Cancer Education Nazli Dizman

Yakup Ergün Raffaele Giusti I'd like to add that for oncologists in low- and middle-income countries (LMICs), social media is not a threat—it’s a lifeline. Before platforms like X (formerly Twitter), global oncology discourse was largely one-sided: knowledge flowed from elite

Thrilled to officially join the 2025–2026 ASCO Trainee & Early Career Advisory Group (ASCO TECAG )! 💼🌟 This powerhouse team brings together trainees from across the country united by a shared mission: championing the next generation of oncologists. Grateful for the

Time to remind everyone. Every committee is put in place in order to make processes more “efficient” but inevitably cause delays and prolongs timelines.